Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFx-Hu2.0 + Pembrolizumab in Advanced Merkel Cell Carcinoma
NCT06947928Phase 3Recruiting
- Sponsor
- TuHURA Biosciences, Inc.
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IFx-Hu2.0 in Merkel cell carcinoma (MCC) (2 arms), sponsored by TuHURA Biosciences, Inc. Primary endpoint: Objective Response Rate at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
IFx-Hu2.0
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06947928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947928.